Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Taxanes-induced cutaneous eruption: another histopathologic mimicker of malignancy.

Prieto-Torres L, Llamas-Velasco M, Machan S, Haro R, de Asis S, Carmo M, Loredo A, Del Puerto C, Fried I, Kempf W, Cerroni L, Requena L.

J Eur Acad Dermatol Venereol. 2016 Apr;30(4):638-44. doi: 10.1111/jdv.13475. Epub 2015 Nov 11.

PMID:
26558745
2.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

3.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

4.

The use of propofol to prevent fetal deceleration during electroconvulsive therapy treatment.

De Asis SJ, Helgeson L, Ostroff R.

J ECT. 2013 Dec;29(4):e57-8. doi: 10.1097/YCT.0b013e318290f9e7.

PMID:
23609517

Supplemental Content

Loading ...
Write to the Help Desk